Volrustomig is an engineered fragment crystallizable (Fc) domain, monovalent bispecific IgG1 monoclonal antibody targeting PD-1 and CTLA-4, key immune checkpoint receptors. It enhances T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. M.W 146.77 kDa

IMM0306 is a bispecific antibody targeting CD20 on B cells and CD47 to block the CD47-SIRPα immune checkpoint. It enhances macrophage and NK cell-mediated phagocytosis and cytotoxicity, exhibiting potential immunostimulating, phagocytosis-inducing and antineoplastic activities, making it a promising immunotherapy for B-cell malignancies. M.W 174.12 kDa

HPN328 is a humanized, trispecific T-cell activating construct (TriTAC) targeting CD3 for T-cell engagement, HSA for half-life extension, and DLL3 on tumor cells. It induces potent T-cell-mediated cytotoxicity against DLL3-expressing small cell lung cancer (SCLC), leading to tumor regression and long-term anti-tumor immunity. M.W 53.06 kDa.

Gen1047 is a bispecific monoclonal antibody targeting CD3 on T cells and B7-H4. It induces T-cell-mediated cytotoxicity against B7-H4-positive cancer cells, making it a potential immunotherapy for malignant solid tumors with immunostimulating and antineoplastic activities. M.W 144.48 kDa.

Afm24 is a human, tetravalent bispecific antibody targeting EGFR on tumor cells and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A) on innate immune cells. It enhances NK cell-mediated cytotoxicity and macrophage-driven phagocytosis, making it a promising immunotherapy with reduced EGFR-related toxicities for cancer treatment. M.W 196.34 kDa.

Tobemstomig is a bispecific antibody targeting PD-1 and LAG-3, designed to enhance T-cell activation. By blocking these immune checkpoints, it promotes a cytotoxic T-cell response and exhibits potential antitumor effects. M.W 145.24 kDa.

Odronextamab is a fully humanized, hinge-stabilized IgG4 bispecific antibody targeting CD20 on B cells and CD3 on T cells. It engages cytotoxic T cells to eliminate malignant B cells and exhibits potent efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma. M.W 145.57 kDa.

Ozoralizumab is a humanized trivalent, bispecific NANOBODY® targeting TNFα with two anti-TNFα domains and an anti-HSA domain. It demonstrates strong anti-arthritis efficacy in human TNF transgenic mice, effective both at arthritis onset and during secondary failure of anti-TNFα IgG therapy. M.W 38.44 kDa.

Cova322 is a bispecific FynomAb targeting TNF and IL-17A, created by fusing a small anti-IL-17A Fynomer to the anti-TNF antibody adalimumab. It shows potent inhibition of TNF and IL-17A in vitro and in vivo, offering potential benefits for inflammatory disease treatment. M.W 161.9 kDa.

Ibi-334 is an ADCC-enhanced bispecific antibody targeting B7-H3 and EGFR, showing potent preclinical efficacy in solid tumors. It blocks EGFR signaling while utilizing a finely tuned B7-H3 arm to enhance inhibition. M.W 145.58 kDa.